A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase III Study of Pemetrexed + Platinum Chemotherapy With or Without Toripalimab (JS001) in Advanced Non-small Cell Lung Cancer (NSCLC) Participants With TKI-resistant EGFR-mutated Tumors

Status: Recruiting

Phase of Trial: Phase III

Latest Information Update: 29 Dec 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Toripalimab (Primary)
Indications Non-small cell lung cancer
Focus Registrational; Therapeutic Use
Sponsors Shanghai Junshi Biosciences

Most Recent Events

23 Dec 2022 Planned number of patients changed from 350 to 440.
23 Dec 2022 Planned End Date changed from 1 May 2022 to 8 Aug 2024.
23 Dec 2022 Planned primary completion date changed from 6 Jul 2021 to 17 Jul 2023.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight